ENTRY       D09535                      Drug
NAME        Mirabegron (JAN/USAN/INN);
            Myrbetriq (TN)
PRODUCT     MYRBETRIQ (Astellas Pharma US)
            MYRBETRIQ (Cardinal Health 107)
            MYRBETRIQ (REMEDYREPACK)
            MYRBETRIQ (REMEDYREPACK)
FORMULA     C21H24N4O2S
EXACT_MASS  396.162
MOL_WEIGHT  396.5059
CLASS       Cardiovascular agent
             DG01456  Adrenergic receptor agonist
              DG01455  beta-Adrenergic receptor agonist
               DG01453  beta3-Adrenergic receptor agonist
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
            Metabolizing enzyme inhibitor
             DG01645  CYP2D6 inhibitor
            Transporter inhibitor
             DG01622  ABCB1 inhibitor
REMARK      Therapeutic category: 2590
            ATC code: G04BD12
            Product: D09535<JP/US>
EFFICACY    Overactive bladder agent, beta3-Adrenergic receptor agonist
TARGET      ADRB3 [HSA:155] [KO:K04143]
  PATHWAY   hsa04020(155)  Calcium signaling pathway
            hsa04080(155)  Neuroactive ligand-receptor interaction
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION CYP inhibition: CYP2D6 [HSA:1565]
            Transporter inhibition: ABCB1 [HSA:5243]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             G GENITO URINARY SYSTEM AND SEX HORMONES
              G04 UROLOGICALS
               G04B UROLOGICALS
                G04BD Drugs for urinary frequency and incontinence
                 G04BD12 Mirabegron
                  D09535  Mirabegron (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Genitourinary Agents
              Antispasmodics, Urinary
               Beta-3 Adrenergic Agonists
                Mirabegron
                 D09535  Mirabegron (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              25  Urogenital and anal organ agents
               259  Miscellaneous
                2590  Miscellaneous
                 D09535  Mirabegron (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01456  Adrenergic receptor agonist
               DG01455  beta-Adrenergic receptor agonist
                DG01453  beta3-Adrenergic receptor agonist
                 D09535  Mirabegron
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D09535  Mirabegron
             Metabolizing enzyme inhibitor
              DG01645  CYP2D6 inhibitor
               D09535  Mirabegron
             Transporter inhibitor
              DG01622  ABCB1 inhibitor
               D09535  Mirabegron
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Rhodopsin family
               Adrenaline
                ADRB3
                 D09535  Mirabegron (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09535
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09535
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09535
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09535
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D09535
             Drug transporters
              D09535
DBLINKS     CAS: 223673-61-8
            PubChem: 96026215
            ChEBI: 65349
            PDB-CCD: H6U
            LigandBox: D09535
ATOM        28
            1   C8x C    16.1700  -31.5700
            2   C8x C    16.1700  -30.1700
            3   C8x C    17.3600  -29.4700
            4   C8x C    18.6200  -30.1700
            5   C8y C    18.6200  -31.5700
            6   C8x C    17.3600  -32.2700
            7   C1c C    19.8100  -32.2700
            8   C1b C    21.0000  -31.5700
            9   N1b N    22.1900  -32.2700
            10  C1b C    23.3800  -31.5700
            11  C1b C    24.5700  -32.2700
            12  C8y C    25.7600  -31.5700
            13  C8x C    25.7600  -30.1700
            14  C8x C    27.0200  -29.4700
            15  C8y C    28.2100  -30.1700
            16  C8x C    28.2100  -31.5700
            17  C8x C    27.0200  -32.2700
            18  N1b N    29.4000  -29.4700
            19  C5a C    30.5900  -30.1700
            20  O5a O    30.5900  -31.5700
            21  O1a O    19.8100  -33.6700
            22  C1b C    31.8053  -29.4749
            23  C8y C    32.9937  -30.1677
            24  C8x C    33.4144  -31.4976
            25  S2x S    34.8140  -31.5091
            26  C8y C    35.2575  -30.1815
            27  N5x N    34.1319  -29.3495
            28  N1a N    36.6163  -29.7524
BOND        30
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     5   7 1
            8     7   8 1
            9     8   9 1
            10    9  10 1
            11   10  11 1
            12   11  12 1
            13   12  13 2
            14   13  14 1
            15   14  15 2
            16   15  16 1
            17   16  17 2
            18   12  17 1
            19   15  18 1
            20   18  19 1
            21   19  20 2
            22    7  21 1 #Down
            23   19  22 1
            24   22  23 1
            25   23  24 2
            26   24  25 1
            27   25  26 1
            28   26  27 2
            29   23  27 1
            30   26  28 1
///
